Hims & Hers Health, Inc. $HIMS Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. lessened its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 34.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,697 shares of the company’s stock after selling 17,357 shares during the period. Pacer Advisors Inc.’s holdings in Hims & Hers Health were worth $679,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. NewEdge Advisors LLC raised its position in shares of Hims & Hers Health by 25.7% during the 1st quarter. NewEdge Advisors LLC now owns 38,173 shares of the company’s stock worth $792,000 after buying an additional 7,800 shares in the last quarter. Avidity Partners Management LP acquired a new position in shares of Hims & Hers Health during the first quarter valued at approximately $1,557,000. Western Wealth Management LLC acquired a new position in shares of Hims & Hers Health during the first quarter valued at approximately $166,000. Bank of America Corp DE raised its holdings in Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after purchasing an additional 2,877,550 shares in the last quarter. Finally, Sunbelt Securities Inc. raised its holdings in Hims & Hers Health by 5,444.7% during the first quarter. Sunbelt Securities Inc. now owns 23,565 shares of the company’s stock worth $489,000 after purchasing an additional 23,140 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Revenue reached approximately $753.2 million, up 38.2% year over year and ahead of the roughly $698.9 million analyst consensus. The company cited strong subscriber growth and broader personalized healthcare offerings as key drivers. Hims & Hers raises annual forecast revenue on strong subscriber growth
• Positive Sentiment: Hims & Hers raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion, above the approximately $3.0 billion consensus. It also issued third-quarter revenue guidance of $880 million-$900 million, above expectations of $845.9 million. Hims & Hers Health Boosts Revenue Target, Swings to Second-Quarter Loss
• Neutral Sentiment: The company said nearly 3 million people rely on its platform, reinforcing the importance of subscriber growth to its long-term expansion strategy. Hims & Hers Health Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Hims & Hers reported a quarterly loss instead of the expected smaller loss, compared with a profit in the prior-year quarter. The earnings miss highlighted continued pressure on margins and profitability despite rapid sales growth. Hims & Hers Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations or fiduciary-duty breaches. These announcements do not establish wrongdoing but add legal and headline risk for shareholders. Kaplan Fox Investigation Announcement

Insiders Place Their Bets

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the completion of the sale, the insider directly owned 181,861 shares of the company’s stock, valued at approximately $6,365,135. This represents a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the transaction, the chief operating officer owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 83,126 shares of company stock worth $2,711,339 over the last three months. Company insiders own 11.76% of the company’s stock.

Hims & Hers Health Stock Performance

HIMS opened at $31.81 on Tuesday. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The firm has a market cap of $7.36 billion, a PE ratio of -353.44, a P/E/G ratio of 88.90 and a beta of 2.40. The business has a fifty day simple moving average of $31.94 and a 200-day simple moving average of $26.07. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. During the same period last year, the firm earned $0.20 earnings per share. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Canaccord Genuity Group increased their price target on Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Citigroup boosted their price objective on Hims & Hers Health from $28.00 to $35.00 and gave the stock a “neutral” rating in a research note on Thursday, July 23rd. Bank of America upped their price objective on Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a report on Thursday, July 9th. UBS Group set a $23.00 target price on Hims & Hers Health in a research note on Friday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $25.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 5th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $31.43.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.